InMed Pharmaceuticals Inc INM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if INM is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.28
- Day Range
- $0.27–0.29
- 52-Week Range
- $0.21–2.08
- Bid/Ask
- $0.30 / $0.30
- Market Cap
- $2.57 Mil
- Volume/Avg
- 3.3 Mil / 1.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.31
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 13
- Website
- https://www.inmedpharma.com
Valuation
Metric
|
INM
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.16 |
Price/Sales | 0.31 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
INM
|
---|---|
Quick Ratio | 5.11 |
Current Ratio | 6.58 |
Interest Coverage | — |
Quick Ratio
INM
Profitability
Metric
|
INM
|
---|---|
Return on Assets (Normalized) | −43.74% |
Return on Equity (Normalized) | −51.62% |
Return on Invested Capital (Normalized) | −51.55% |
Return on Assets
INM
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk A/S ADR
NVO
| Zjcncmrhc | Rcglr | $565.6 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Swbfgst | Qfpcwsh | $127.8 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Skrrzmxln | Fbvcfgv | $117.3 Bil | |||
Moderna Inc
MRNA
| Wjpzxnhwc | Brfg | $46.1 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Blvkrnnys | Wdslqym | $29.7 Bil | |||
argenx SE ADR
ARGX
| Jllgpkst | Yrcl | $28.8 Bil | |||
BioNTech SE ADR
BNTX
| Wxkttcbm | Pgf | $20.7 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Vynqrvwy | Dzflbn | $16.1 Bil | |||
United Therapeutics Corp
UTHR
| Cbgrydhys | Tmb | $14.9 Bil | |||
Incyte Corp
INCY
| Nqtgjkdf | Pqmlpj | $13.5 Bil |